Year: 2025

Twin Hospitality Group Inc.Twin Peaks Opens New Lodge in Algonquin, Illinois, on March 17Ultimate sports lodge brings scratch-made food, 29-degree draft beer, and premium sports watching atmosphere to the Chicago area — just in time for St. Patrick’s Day Chicago, Ill., March 17, 2025 (GLOBE NEWSWIRE) — Twin Hospitality Group Inc. (Nasdaq: TWNP), the parent company of Twin Peaks Restaurant, is bringing the luck of the lodge to the Chicago area with its newest location in Algonquin, opening Monday, March 17, creating the perfect spot for St. Patrick’s Day celebrations. Known for its 29-degree draft beer, made-from-scratch kitchen and unbeatable game-day environment, this marks Twin Peaks’ fourth location in Illinois and the 116th lodge across the U.S. and Mexico. Located at 1520 South Randall Road in the Algonquin Commons,...

PHOENIX, March 17, 2025 (GLOBE NEWSWIRE) — WillScot Holdings Corporation (“WillScot” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary space solutions, today announced it is amending the Consent Solicitations of its indirect subsidiary, Williams Scotsman, Inc. (“WSI”), soliciting consents (“Consents”) from holders of its existing 6.625% Senior Secured Notes due 2029 (the “2029 Notes”) and the holders of its 7.375% Senior Secured Notes due 2031 (the “2031 Notes” and, together with the 2029 Notes, the “Existing Notes”) as of the record date of March 11, 2025 (the “Record Date”) for the adoption of certain amendments (the “Proposed Amendments”) to the indentures governing the Existing Notes. The Consent Solicitations for each series of Existing Notes (collectively, the “Consent Solicitations” and, with respect to each...

-Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), including improvement on the trial’s primary outcome measure- -Plan to initiate Phase 3 trial in mid-2026 following meeting with regulatory authorities- -Awarded 2024 Prix Galien USA Award as “Best Startup” by the Galien Foundation- BOSTON, March 17, 2025 (GLOBE NEWSWIRE) —  CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today reported its financial results for the fourth quarter and full year ended December 31, 2024. “Following the highly encouraging 16-week extension results from our Phase 2b RewinD-LB trial, we believe we have established proof-of-concept for neflamapimod as a potential...

Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across multiple tumor types PLN-101095 was generally well tolerated across all doses SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial evaluating PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI) -refractory advanced or metastatic solid tumors. Interim results demonstrated PLN-101095 anti-tumor activity in combination with pembrolizumab, with three partial responses observed in cohort three at the 1000 mg administered orally twice daily (BID) dose, representing a...

The US Government Granted Athena GTX a $2,866,000 Final Development Contract Award! JACKSON CENTER, Pa., March 17, 2025 (GLOBE NEWSWIRE) — Halberd Corporation (OTC: HALB) partnered with Athena GTX on a profit-sharing agreement over a year ago. This enabled Halberd to utilize Athena’s expertise and experience in dealing with the federal government. Of the two technologies associated with Traumatic Brain Injuries (TBI)/Suicide Ideation for which we chose to pursue government funding, Athena’s success via the WatchDawg® Pilot Study was chosen to lead the Suicide Ideation treatment project, while Halberd, via the successful Mississippi State University initial animal tests, leads the TBI mitigation nasal spray development program. The website we established to do the hard work on market development and FDA clearance for our LDX adjunct...

SALT LAKE CITY, Utah, March 17, 2025 (GLOBE NEWSWIRE) — Sintx Technologies, Inc. (NASDAQ: SINT) (“Sintx” or the “Company”), a leader in advanced ceramics for medical device and technical applications, today announced that Dr. Sonny Bal has retired as Chairman of the Board, and the Board of Directors has unanimously appointed Eric Olson, the Company’s Chief Executive Officer, as its new Chairman, effective immediately. Dr. Bal, who has served as Chairman since 2015, has played a crucial role in driving Sintx’s transformation, strengthening its core business, and positioning the Company for growth in the advanced materials sectors. He will continue to support the Company as a member of the Board of Directors, ensuring continuity as Sintx executes on its strategic objectives. “On behalf of the Board and the entire Sintx team, I want...

 New Analyses Related to Aficamten Expand on its Metabolism Pathways,Treatment Effect Associated with Combination Therapy with Disopyramideand Longer-Term Effect on Cardiac Structure and Function SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten, an investigational cardiac myosin inhibitor, and hypertrophic cardiomyopathy (HCM), at the American College of Cardiology (ACC) Annual Scientific Session & Expo taking place from March 29, 2025–March 31, 2025 in Chicago, IL. “We are pleased to be sharing several new analyses relating to aficamten at the upcoming ACC Scientific Session & Expo,” said Stephen Heitner, M.D., Vice President, Head of Clinical Research. “The presentations describe the drug metabolism of aficamten,...

Press Release March 17, 2025 Signify share repurchase period update Eindhoven, the Netherlands – Signify (Euronext: LIGHT), the world leader in lighting, today announced that it has repurchased 145,733 shares in the period March 10 to March 14, 2025. The shares were repurchased at an average price of EUR 20.51 per share and an aggregate amount of EUR 3.0 million. Signify will use these repurchased shares to cover obligations arising from Signify’s long-term incentive performance share plan and other employee share plans. The repurchases were made as part of the company’s share repurchase program, which was announced on February 4, 2025. The total number of shares repurchased under this program to date is 830,209 shares for a total consideration of EUR 17.2 million. Details on the share buyback transactions can be found here.   —...

    The Annual Meeting is the foremost educational and scientific event for gynecologic oncologistsStenoparib has shown clinical benefit in heavily pre-treated patients, including those with platinum-resistant and refractory ovarian cancerFindings may reflect stenoparib’s dual PARP/Wnt pathway inhibitionBoston (March 17, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor— announced the presentation of new clinical data from its ongoing Phase 2 trial with stenoparib monotherapy in advanced Ovarian Cancer at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer, held March 14-17 in Seattle, Washington. SGO is the world’s premier organization for...